Therapeutic Action
Cardiotonic
PDF page 118
Loading InternPractice…
Drug reference
Cardiotonic
PDF page 118
Supraventricular arrhythmias (fibrillation, flutter, paroxysmal tachycardia) Heart failure
PDF page 118
Do not administer to patients with bradycardia, ill defined arrhythmia, coronary artery disease. It is essential to monitor heart rate in the initial stage of treatment. May cause in the event of overdose: gastrointestinal disturbances (nausea, vomiting, diarrhoea), blurred vision, headache, confusion, conduction and rhythm disorders. If so, reduce dose or stop treatment. Do not combine with calcium, particularly by IV route (serious arrhythmias). Monitor combination with: amiodarone, macrolides, itraconazole, quinine, chloroquine (increased digoxin concentration); potassium-depleting drugs: diuretics, corticosteroids, amphotericin B (increased risk of digoxin toxicity). Monitor if possible serum potassium level in patients taking potassium-depleting drugs and serum creatinine level in patients with renal impairment. Do not administer simultaneously with antacids such as aluminium hydroxide, etc., administer 2 hours apart. Pregnancy: no contra-indication Breast-feeding: no contra-indication
PDF pages 118, 119
250 micrograms (0.25 mg) tablet
PDF page 118
Adult: 125 to 250 micrograms (0.125 to 0.25 mg) once daily Reduce the dose by half in older patients and in patients with renal impairment.
PDF page 118
According to clinical response
PDF page 118
– Below 25 °C
PDF page 119
125 to 250 micrograms (0.125 to 0.25 mg) once daily
PDF page 118